Albendazole: a new single dose anthelmintic. Study in 1455 patients

Acta Trop. 1984 Mar;41(1):87-90.


Albendazole has been tested in an open trial conducted in France, seven countries of West-Africa, Martinique and the People's Republic of China in a total of 1455 patients harboring single or mixed infections caused by round-worms, pinworms, hookworms and whipworms. All patients were closely observed before and after treatment for clinical side effects and hematology and clinical chemistry values were done in about 5% of the cases. Fecal samples obtained before and approximately 15, 16 and 17 days after treatment were examined using the Kato test, and when negative, a concentration technic. In case of ancylostomiasis, a coproculture was carried out for species identification. Following a single oral dose, albendazole was highly effective in enterobiasis (100%), ascariasis (89%), ancylostomiasis caused by Necator americanus (88%) and trichuriasis (70%). The drug did not procedure any significant adverse reactions or modifications of the hematological and clinical blood chemistry values and only 6% of the 1455 patients reported minor side effects.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Africa, Western
  • Albendazole
  • Anthelmintics / therapeutic use*
  • Ascariasis / drug therapy
  • Benzimidazoles / adverse effects
  • Benzimidazoles / therapeutic use*
  • Child
  • Child, Preschool
  • China
  • Clinical Trials as Topic
  • Female
  • France
  • Humans
  • Male
  • Martinique
  • Middle Aged
  • Necatoriasis / drug therapy
  • Nematode Infections / drug therapy*
  • Oxyuriasis / drug therapy
  • Trichuriasis / drug therapy


  • Anthelmintics
  • Benzimidazoles
  • Albendazole